Aptevo Therapeutics announced positive clinical trial results for its lead candidate, mipletamig, in high-risk acute myeloid leukemia patients. The 93% clinical benefit rate and 79% complete remission rate significantly outperform existing treatments, indicating a potential breakthrough for a difficult-to-treat patient population.
Aptevo Therapeutics reported a 93% clinical benefit rate for its drug mipletamig in a triplet therapy for frontline acute myeloid leukemia (AML) patients with TP53 mutations. This is a significant finding because TP53-mutated AML is a high-risk group with historically poor responses to treatment. The 79% complete remission rate observed with mipletamig compares favorably to the 41% composite remission rate of the current standard of care, venetoclax and azacitidine alone. This positive data could be a major long-term catalyst for APVO, as it addresses a critical unmet medical need. However, the stock was down 22% on the news, suggesting short-term profit-taking or broader market sentiment overshadowing the positive trial data, creating a potential opportunity for traders who believe in the long-term value of the drug.